



11/28/01

UTILITY PATENT APPLICATION TRANSMITTAL <small>For new nonprovisional applications under 37 CFR 1.53(b)</small>	Attorney Docket No.	216457US0CONT	BOX 589/1
	First Inventor or Application Identifier	Masafumi T. UCHI	
	Title	HIV-SPECIFIC CTL INDUCING PEPTIDES AND MEDICAMENTS FOR PREVENTING OR TREATING AIDS COMPRISING THE PEPTIDES	
Assignee Name:		AJINOMOTO CO., INC.	
Assignee Address:		15-1, Kyobashi 1-Chome, Chuo-Ku, Tokyo 104-0031, JAPAN	

11/28/01
PTO
09/08/01
11/28/01

APPLICATION ELEMENTS <i>See MPEP chapter 600 concerning utility patent application contents</i>	ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<ol style="list-style-type: none"><input checked="" type="checkbox"/> Fee Transmittal Form (e.g. PTO/SB/17) (Submit an original and a duplicate for fee processing)<input checked="" type="checkbox"/> Specification Total Sheets 21<input checked="" type="checkbox"/> Drawings (35 U.S.C. 113) Total Sheets 2<input type="checkbox"/> Oath or Declaration Total Pages 1<ol style="list-style-type: none"><input type="checkbox"/> Newly executed (original or copy)<input type="checkbox"/> Copy from a prior application (37 C.F.R. §1.63(d)) (for continuation / divisional w/ box 17 completed)<ol style="list-style-type: none"><input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §1.63(d)(2) and 1.33(b).<input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)<input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)<ol style="list-style-type: none"><input checked="" type="checkbox"/> Computer Readable Form (CRF)Specification or Sequence Listing on:<ol style="list-style-type: none"><input type="checkbox"/> CD-ROM or CD-R (2 copies); or<input checked="" type="checkbox"/> Paper<input type="checkbox"/> Statements verifying identity of above copies	ACCOMPANYING APPLICATION PARTS <ol style="list-style-type: none"><input type="checkbox"/> Assignment Papers (cover sheet & document(s))<input checked="" type="checkbox"/> Application Data Sheet, 2 Pages, See 37 CFR 1.76<input type="checkbox"/> 37 C.F.R. §3.73(b) Statement (when there is an assignee) <input type="checkbox"/> Power of Attorney<input type="checkbox"/> English Translation Document (if applicable)<input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations<input checked="" type="checkbox"/> Preliminary Amendment<input checked="" type="checkbox"/> White Advance Serial No. Postcard<input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27<input checked="" type="checkbox"/> Other: Request for Priority
7. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below: <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no.: Prior application information: Examiner: Group Art Unit:	
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.	
18. Amend the specification by inserting before the first line the sentence: <input checked="" type="checkbox"/> This application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Division <input type="checkbox"/> Continuation-in-part (CIP) of application Serial No. PCT/JP00/03455 Filed on May 29, 2000 <input type="checkbox"/> Which was published in English <input type="checkbox"/> Which was not published in English <input type="checkbox"/> This application claims priority of provisional application Serial No. Filed	
19. CORRESPONDENCE ADDRESS  22850 (703) 413-3000 FACSIMILE: (703) 413-2220	

Name:	Norman F. Oblon	Registration No.:	24,618
Signature:		Date:	11/28/01
Name:	Daniel J. Pereira, Ph.D.	Registration No.:	45,518

Socket No.

216457US0CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR(S) Masafumi TAKIGUCHI et al

SERIAL NO: New Application

FILING DATE: Herewith

FOR: HIV-SPECIFIC CTL INDUCING PEPTIDES AND MEDICAMENTS FOR PREVENTING OR TREATING AIDS COMPRISING THE PEPTIDES

FEE TRANSMITTAL

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	3 - 20 =	0	× \$18 =	\$0.00
INDEPENDENT CLAIMS	1 - 3 =	0	× \$84 =	\$0.00
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS (If applicable)			+ \$280 =	\$0.00
<input checked="" type="checkbox"/> LATE FILING OF DECLARATION			+ \$130 =	\$130.00
BASIC FEE				\$740.00
TOTAL OF ABOVE CALCULATIONS				\$870.00
<input type="checkbox"/> REDUCTION BY 50% FOR FILING BY SMALL ENTITY				\$0.00
<input type="checkbox"/> FILING IN NON-ENGLISH LANGUAGE			+ \$130 =	\$0.00
<input type="checkbox"/> RECORDATION OF ASSIGNMENT			+ \$40 =	\$0.00
TOTAL				\$870.00

Please charge Deposit Account No. 15-0030 in the amount of


A duplicate copy of this sheet is enclosed.

A check in the amount of **\$870.00** to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 15-0030.
A duplicate copy of this sheet is enclosed.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518

Date:

11/28/01



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 10/00)